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Low-molecular-weight heparin in patients with advanced cancer: A
phase 3 clinical trial
Sideras K, Schaefer PL, Okuno SH, et al. Mayo Clin Proc 2006;81:758-67.
Conclusion: Low-molecular-weight heparin does not provide survival
benefit in patients with advanced cancer.
Summary: It has been suggested that patients with cancer who develop
venous thromboembolism (VTE) and are treated with low-molecular-
weight heparin have a survival advantage over those treated with unfraction-
ated heparin (Am J Med 1996;100:269-277 and Ann Intern Med 1999;
130:800-809). The authors therefore sought to assess whether low-
molecular-weight heparin might provide a survival advantage in patients
with advanced cancer.
This was a randomized clinical trial conducted between December
1998 and June 2001. Patients with advanced cancer were randomized to
receive low-molecular-weight heparin or placebo. The study began as a
double-blinded placebo-controlled trial with patients receiving injections
daily of saline or 5000 U of low-molecular-weight heparin. Recruitment for
the trial was low; therefore, the placebo arm was eliminated midway through
the study. At this point, the study became open labeled, and patients
received low-molecular-weight heparin injections and standard clinical care,
or standard clinical care alone. The primary study end point was overall
survival.
There were 138 patients analyzed. Median survival for the combined
standard-care and placebo groups was 10.5months (95% confidence interval
[CI], 7.6 to 12.2 months). Median survival for the low-molecular-weight
heparin arms of the trial was 7.3 months (95% CI, 4.8 to 12.2). This was not
significantly different from the placebo group (P  .46). Median survival
times for unblinded and blinded low-molecular-weight heparin groups were
9.0 months and 6.2 months, respectively. Median survival time was 10.5
months in the standard-care group and 10.3 months in the placebo-blinded
group. There was a 6% rate of significant VTE in the low-molecular-weight
heparin arms and a 7% rate in the control arms. Major bleeding was 7% in the
control arms and 3% in the low-molecular-weight heparin arms.
Comment: It has been suggested for a number of years that low-
molecular-weight heparin may confer a survival advantage over unfraction-
ated heparin in patients with VTE and cancer. A pleiotropic effect of
low-molecular-weight heparin was postulated. This study argues against
such an effect. Weaknesses of the study include changing its design in
mid-course and inclusion of four different groups of cancer patients, perhaps
masking a treatment effect in one group vs another. The trial did demon-
strate safety of low-molecular-weight heparin in patients with advanced
cancer.
Determinants of arterial wall remodeling during lipid-lowering ther-
apy: Serial intravascular ultrasound observations from the reversal of
atherosclerosis with aggressive lipid Lowering therapy (REVERSAL)
trial
Schoenhagen P, Tuzcu EM, Apperson-Hansen C, et al. Circulation 2006;
113:2826-34.
Conclusion: Plaque stabilization therapy with statin medications re-
sults in constrictive remodeling of the arterial wall and appears related to the
anti-inflammatory effects of statin medications.
Summary: The authors sought to study remodeling of coronary arter-
ies during plaque-stabilizing therapy and to relate this remodeling to mark-
ers of lipid metabolism and inflammation.
The Reversal of Atherosclerosis with Aggressive Lipid Lowering Ther-
apy (REVERSAL) trial examined reversal of coronary artery atherosclerosis
during 18 months of intensive vs moderate lipid-lowering therapy. The
authors identified 210 patients with mild luminal narrowing coronary le-
sions. External elastic membrane (EEM) area, lumen area, and plaque area
were determined at the site of the coronary lesions and at a reference site
proximal to the lesions. Measurements were taken at baseline and during
follow-up. The remodeling ratio (RR) was calculated by dividing EEM area
of the lesion by EEM reference area. Changes in remodeling and changes in
plaque area were correlated with lipid profile and inflammatory markers.
The lesions examined showed a progression in plaque area (8.9% 
25.7%) and a decrease in RR (3.0%  11.2%) during follow-up. Direct
effects with RR were correlated with percentage change in plaque area (P
.0001), baseline RR (P .0001), and baseline lesion lumen area (P .019)
as well as change in high sensitivity C-reactive protein levels (P .027) and
baseline hypertension (P .014). Age (P .037) and percentage change in
triglyceride levels (P  .049) demonstrated significant inverse relationships
with RR during follow-up. There were no associations between changes in
treatment group (moderate vs high-intensity statin therapy) levels of low-
density (LDL) or high-density lipoprotein (HDL) cholesterol.
Comment: Plaque regression and stabilization appears to be accompa-
nied by a reduction in vessel size. Correlation of these effects with C-reactive
protein, but not serum levels of HDL or LDL cholesterol, suggest drugs
targeting arterial inflammation may be more effective than those targeting
simple measures of lipid metabolism. The anti-inflammatory effects of statins
may turn out to be more important than their cholesterol-lowering effects.
Incidence of new brain lesions after carotid stenting with and without
cerebral protection
Kastrup A, Nagele T, Groschel K, et al. Stroke 2006; 36:2312-6.
Conclusion: New cerebral infarcts detected by diffusion-weighted
imaging (DWI) are common after protected and unprotected carotid artery
stenting, but fewer DWI lesions occur after protected carotid artery stenting.
Summary: DWI is currently the most sensitive tool to detect early
cerebral ischemia (Stroke 1998;29:1783-90). In this study, the authors used
DWI to compare the number, frequency, and size of new DWI lesions after
protected and unprotected carotid artery stenting and sought to determine
the clinical significance of these lesions. DWI was obtained before carotid
artery stenting and 48 hours after carotid artery stenting. Clinical end
points included stroke and death 30 days.
There were 139 patients treated with protected and 67 patients treated
with unprotected carotid artery stenting. After protected carotid artery
stenting, the proportion of patients with new ipsilateral DWI lesions was
lower than after unprotected carotid artery stenting (49% vs 67%; P  .05).
The number of new ipsilateral DWI lesions was also lower after protected vs
unprotected carotid artery stenting (median, 0 [interquartile range, 0 to 0.3]
vs median, 1 [interquartile range, 0 to 4]; P  .05). Most of the new DWI
lesions were asymptomatic and10 mm in diameter. The clinical outcomes
of patients treated with cerebral protection at 30 days did not differ signifi-
cantly from those with patients not treated with cerebral protection (4.3%
stroke and death vs 7.5% stroke and death, P  NS). The number of new
DWI lesions was, however, significantly higher in patients with postproce-
dure stroke (median, 7.5 [interquartile range, 1.5 to 17]) vs patients without
stroke (median, 0 [interquartile range, 1 to 3.25]; P  .01).
Comment: Carotid artery stenting results in a large number of silent
cerebral infarcts. Most are asymptomatic, but the number of DWI infarcts
correlates with clinical stroke. This suggests that detection of DWI infarcts
may be a reasonable surrogate end point for comparison of cerebral produc-
tion devices used in carotid artery stenting.
Silent ischemia after neuroprotected percutaneous carotid stenting: A
diffusion-weighted MRI study
Pinero P, Gonzalez A, Mayol A, et al. AJNR Am J Neuroradiol 2006;27:
1338-45.
Conclusions: New ischemic foci detected by diffusion-weighted im-
aging (DWI) occurred in 17% of cases after carotid artery stenting. DWI
lesions did not correlate with microemboli signals detected by transcranial
Doppler, but did correlate with occurrence of transient ischemic attack
(TIA).
Summary: Carotid artery stenting using a distal filter embolic protec-
tion device was performed in 162 patients (75.3% symptomatic). Four
different types of embolic protection devices were used: EPI and EZ filter
wires (Boston Scientific/Target Therapeutics, Fremont, Calif), Spider (ev3,
Plymouth, Minn), and Accunet (Guidant, Santa Clara, Calif). DWI was
performed72 hours of carotid artery stenting and 24 hours after stenting.
Middle cerebral artery transcranial Doppler ultrasonography was used to
monitor 95 (58.6%) of the 162 patients to detect microemboli ipsilateral to
the stented carotid artery.
After stenting, 28 patients (7.3%) showed 58 new DWI ischemic
lesions, and 13 (46.4%) had multiple DWI lesions. A total of 67.9% of new
lesions were in the vascular territory supplied by the carotid artery treated.
DWI lesions also occurred in the contralateral middle cerebral artery in one
patient and in the posterior fossa of four patients. The appearance of new
DWI lesions and the occurrence of TIA was significantly correlated (P 
.03). Of the patients studied with transcranial Doppler, microembolic
signals were detected in 92.6%. There was no relationship between micro-
embolic signals and new DWI lesions. There was also no relationship
between new DWI lesions and patient demographics, clinical presentation,
vascular risk factors, plaque characteristics, or type of stent or cerebral
protection device.
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